Cargando…

Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs

BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of suc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yuki, Hara, Konan, Yoo, Byung-Kwang, Tomio, Jun, Kobayashi, Yasuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824135/
https://www.ncbi.nlm.nih.gov/pubmed/31675967
http://dx.doi.org/10.1186/s12913-019-4598-8
_version_ 1783464681258614784
author Ito, Yuki
Hara, Konan
Yoo, Byung-Kwang
Tomio, Jun
Kobayashi, Yasuki
author_facet Ito, Yuki
Hara, Konan
Yoo, Byung-Kwang
Tomio, Jun
Kobayashi, Yasuki
author_sort Ito, Yuki
collection PubMed
description BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over. METHODS: We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments. RESULTS: Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases. CONCLUSIONS: Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences.
format Online
Article
Text
id pubmed-6824135
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68241352019-11-06 Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs Ito, Yuki Hara, Konan Yoo, Byung-Kwang Tomio, Jun Kobayashi, Yasuki BMC Health Serv Res Research Article BACKGROUND: Higher income population tend to prefer brand-name to generic drugs, which may cause disparity in access to brand-name drugs among income groups. A potential policy that can resolve such disparity is imposing a greater co-payment rate on high-income enrollees. However, the effects of such policy are unknown. We examined how patients’ choice between brand-name and generic drugs are affected by the unique income-based co-payment rates in Japan; 10% for general enrollees and 30% for those with high income among the elderly aged 75 and over. METHODS: We drew on cross-sectional price variation among commonly prescribed 311 drugs using health insurance claims data from a large prefecture in Japan between October 2013 and September 2014 to identify between-income-group differences in responses to differentiated payments. RESULTS: Running 311 multivariate logistic regression models controlling individual demographics, the median estimate indicated that high-income group was 3% (odds ratio = 0.97) less likely to choose a generic drug than the general-income group and the interquartile estimates ranged 0.92–1.02. The multivariate feasible generalized least squares model indicated high-income group’s higher likelihood to choose brand-name drugs than the general-income group without co-payment rate differentiation (p < 0.001). Such gap in the likelihood was attenuated by 0.4% (p = 0.027) with an US$1 increase in the difference in additional payment/month for brand-name drugs between income groups — no gap with US$10 additional payment/month. This attenuation was observed in drugs for chronic diseases only, not for acute diseases. CONCLUSIONS: Income-based co-payment rates appeared to reduce disparity in access to brand-name drugs across income groups, in addition to reducing total medical expenditure among high-income group who shifted from brand-name drugs to generic ones due to larger drug price differences. BioMed Central 2019-11-01 /pmc/articles/PMC6824135/ /pubmed/31675967 http://dx.doi.org/10.1186/s12913-019-4598-8 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ito, Yuki
Hara, Konan
Yoo, Byung-Kwang
Tomio, Jun
Kobayashi, Yasuki
Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title_full Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title_fullStr Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title_full_unstemmed Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title_short Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs
title_sort can income-based co-payment rates improve disparity? the case of the choice between brand-name and generic drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824135/
https://www.ncbi.nlm.nih.gov/pubmed/31675967
http://dx.doi.org/10.1186/s12913-019-4598-8
work_keys_str_mv AT itoyuki canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs
AT harakonan canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs
AT yoobyungkwang canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs
AT tomiojun canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs
AT kobayashiyasuki canincomebasedcopaymentratesimprovedisparitythecaseofthechoicebetweenbrandnameandgenericdrugs